HCA Healthcare, Inc.
HCA · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 60.23B | 23.18B | 9.05B | 5.64B | 19.44 |
| 2023 FY | 64.97B | 25.58B | 9.63B | 5.24B | 19.24 |
| 2024 FY | 70.60B | 28.68B | 10.55B | 5.76B | 22.27 |
| 2025 FY | 75.60B | 31.37B | 11.97B | 6.78B | 28.62 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 52.44B | 52.51B | 908.00M | 40.20B | -2.77B |
| 2023 FY | 56.21B | 55.15B | 935.00M | 41.86B | -1.77B |
| 2024 FY | 59.51B | 58.96B | 1.93B | 45.24B | -2.50B |
| 2025 FY | 60.72B | 63.49B | 1.04B | 50.20B | -6.03B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 8.52B | -4.40B | 4.13B | -653.00M | -543.00M |
| 2023 FY | 9.43B | -4.74B | 4.69B | -661.00M | 27.00M |
| 2024 FY | 10.51B | -4.88B | 5.64B | -690.00M | 998.00M |
| 2025 FY | 12.64B | -4.94B | 7.69B | -679.00M | -893.00M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 69.67B | 108.96B | — | — | — |
| 2023 FY | 73.73B | 114.66B | — | — | — |
| 2024 FY | 77.62B | 120.92B | — | — | — |
| 2025 FY | 107.71B | 156.87B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 18.61B | 7.62B | 2.97B | 1.65B | 6.91 |
| 2025 Q3 | 19.16B | 8.02B | 2.97B | 1.64B | 7.05 |
| 2025 Q4 | 19.51B | 8.18B | 3.18B | 1.88B | 8.14 |
| 2026 Q1 | 19.11B | 2.86B | 2.86B | 1.62B | 7.15 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 59.54B | 60.77B | 939.00M | 46.36B | -4.39B |
| 2025 Q3 | 59.75B | 61.91B | 997.00M | 46.35B | -5.34B |
| 2025 Q4 | 60.72B | 63.49B | 1.04B | 50.20B | -6.03B |
| 2026 Q1 | 61.45B | 64.43B | 940.00M | 49.85B | -6.30B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 4.21B | -1.18B | 3.03B | -171.00M | -121.00M |
| 2025 Q3 | 4.42B | -1.29B | 3.13B | -166.00M | 58.00M |
| 2025 Q4 | 2.36B | -1.49B | 870.00M | -162.00M | 43.00M |
| 2026 Q1 | 2.01B | -1.12B | 895.00M | -183.00M | -100.00M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 92.68B | 138.10B | — | — | — |
| 2025 Q3 | 103.34B | 148.69B | — | — | — |
| 2025 Q4 | 107.71B | 156.87B | — | — | — |
| 2026 Q1 | 107.26B | 156.17B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |